Dermatology
T-oligos trigger anticancer activity in melanoma cells
Published in Gene Therapy Weekly, December 9th, 2004
"Melanoma is the most fatal skin cancer, often highly resistant to chemotherapy. Here we show that treatment with an 11-base DNA oligonucleotide homologous to the telomere 3' overhang sequence (T-oligo) induces apoptosis of several established human melanoma cell lines, including the aggressive MM-AN line, whereas normal human melanocytes exposed to the same or higher T-oligo concentrations show only transient cell cycle arrest, implying that malignant cells are more sensitive to T-oligo effects," scientists in the United States report.
"When MM-AN cells were briefly exposed to T-oligo in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2004-12-09)
More Articles from Gene Therapy Weekly
- Cancer Vaccines
Interleukin-15 transfection plus CD8+ T cells cause colon cancer rejection - Gastroenterology
Cytotoxic gene therapy is selective for human pancreatic cancer cells - Urological Oncology
Bladder tumors respond to non-viral tumor necrosis factor-alpha gene transfer - Viral Vectors
Biological and physical titers should be counted in virus-based gene therapy - Adenovirus
Nuclear localization of adenovirus E4orf4 protein correlates with cell death - Alcoholic Liver Disease
Intracellular SAH removal may be therapeutic option in alcoholic liver disease - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
